Table 2.
Univariate analysis on patients outcome.
| Patients Characteristics | CR | OS | DFS | |||
|---|---|---|---|---|---|---|
| HR | p | HR | p | HR | p | |
| HDS | 0.94 (0.44–2.03) | 0.8731 | 0.86 (0.59–1.26) | 0.4318 | 0.82 (0.54–1.23) | 0.3276 |
| HSCT | - | - | 0.31 (0.18–0.51) | 0.0000 | 0.29 (0.17–0.48) | <0.0001 |
| Age > 60 | 0.21 (0.09–0.45) | 0.0001 | 2.67 (1.81–3.95) | 0.0000 | 1.92 (1.22–3.02) | 0.0047 |
| Sex male | 1.67 (0.77–3.79) | 0.2019 | 0.95 (0.65–1.39) | 0.7982 | 1.06 (0.7–1.58) | 0.7901 |
| De novo | 2.62 (0.94–6.69) | 0.0503 | 0.73 (0.42–1.27) | 0.2665 | 0.76 (0.41–1.43) | 0.3975 |
| ECOG PS 2–3 | 0.25 (0.09–0.73) | 0.0076 | 2.24 (1.25–4.01) | 0.0065 | 1.06 (0.46–2.43) | 0.886 |
| WBC count > 50 | 0.74 (0.34–1.7) | 0.4621 | 1.61 (1.09–2.39) | 0.0179 | 1.37 (0.89–2.12) | 0.1533 |
| NPM1 | 1.76 (0.82–3.92) | 0.1541 | 0.71 (0.48–1.04) | 0.0780 | 0.76 (0.51–1.14) | 0.1864 |
| VAF ≤ 0.4 | 2.18 (0.87–6.27) | 0.1162 | 0.67 (0.42–1.05) | 0.0785 | 0.89 (0.57–1.39) | 0.6075 |
| VAF > 0.4 | 1.3 (0.5–3.81) | 0.6031 | 0.8 (0.48–1.33) | 0.3924 | 0.59 (0.33–1.08) | 0.0866 |
| FLT3-ITD | 0.79 (0.34–1.93) | 0.5811 | 2.23 (1.5–3.32) | 0.0001 | 2.18 (1.43–3.33) | 0.0003 |
| FLT3-ITD low | 0.95 (0.29–4.29) | 0.9380 | 1.67 (0.9–3.08) | 0.1032 | 1.55 (0.8–3.04) | 0.1966 |
| FLT3-ITD high | 0.87 (0.34–2.51) | 0.7813 | 2.43 (1.56–3.78) | 0.0001 | 2.6 (1.62–4.18) | 0.0001 |
| DNMT3A | 1.01 (0.47–2.25) | 0.9799 | 1.25 (0.85–1.83) | 0.2606 | 1.49 (0.99–2.23) | 0.0553 |
| TET2 | 0.23 (0.1–0.54) | 0.0006 | 1.38 (0.85–2.24) | 0.1926 | 0.94 (0.5–1.76) | 0.8357 |
| RUNX1 | 0.42 (0.17–1.08) | 0.0590 | 2.25 (1.43–3.55) | 0.0005 | 1.95 (1.15–3.3) | 0.0132 |
| IDH2 | 0.68 (0.25–2.17) | 0.4754 | 0.77 (0.4–1.47) | 0.4247 | 1.05 (0.56–1.97) | 0.8732 |
| CEBPA2 * | 3.37 (0.66–61.69) | 0.2450 | 0.26 (0.1–0.71) | 0.0088 | 0.21 (0.06–0.65) | 0.007 |
| FLT3_PM | 1.57 (0.42–10.17) | 0.5605 | 0.45 (0.2–1.04) | 0.0608 | 0.38 (0.16–0.94) | 0.0371 |
| IDH1 | 0.98 (0.3–4.36) | 0.9714 | 0.95 (0.51–1.78) | 0.8781 | 0.98 (0.51–1.89) | 0.9575 |
| ASXL1 | 0.25 (0.09–0.73) | 0.0076 | 1.54 (0.86–2.76) | 0.1434 | 1.3 (0.63–2.68) | 0.4827 |
| CEBPA1 * | 2.32 (0.44–42.85) | 0.4243 | 0.56 (0.23–1.39) | 0.2133 | 0.63 (0.25–1.55) | 0.3141 |
| PTPN11 | 2.95 (0.57–54.09) | 0.3022 | 0.46 (0.19–1.13) | 0.0908 | 0.58 (0.26–1.33) | 0.2018 |
| SRSF2 | 0.12 (0.04–0.34) | 0.0001 | 1.43 (0.77–2.67) | 0.2596 | 0.8 (0.29–2.17) | 0.6553 |
| NRAS | 0.74 (0.22–3.37) | 0.6557 | 1.46 (0.78–2.72) | 0.2387 | 1.31 (0.64–2.71) | 0.4607 |
| KMT2A-PTD | 2.42 (0.46–44.57) | 0.4027 | 1.34 (0.67–2.67) | 0.4037 | 1.44 (0.72–2.88) | 0.298 |
| STAG2 | 0.35 (0.1–1.36) | 0.0990 | 1.33 (0.61–2.88) | 0.4712 | 1.3 (0.52–3.23) | 0.5691 |
| BCOR | 1.95 (0.36–36.43) | 0.5310 | 1.58 (0.73–3.44) | 0.2456 | 1.52 (0.66–3.51) | 0.3258 |
| KRAS | 1.84 (0.34–34.31) | 0.5648 | 0.81 (0.33–2) | 0.6546 | 1.1 (0.48–2.52) | 0.8178 |
| WT1 | 1.84 (0.34–34.31) | 0.5648 | 0.8 (0.32–1.95) | 0.6185 | 0.75 (0.28–2.04) | 0.5736 |
| GATA2 | >99.99 (0–NA) | 0.9894 | 0 (0–Inf) | 0.9953 | 0 (0–Inf) | 0.9954 |
| SF3B1 | 1.32 (0.23–24.91) | 0.7976 | 1.42 (0.66–3.06) | 0.3689 | 1.8 (0.83–3.9) | 0.1348 |
| U2AF1 | 1.32 (0.23–24.91) | 0.7976 | 2.69 (1.3–5.55) | 0.0075 | 3.57 (1.64–7.74) | 0.0013 |
| FLT3wt, NPM1 wt | 0.58 (0.26–1.28) | 0.1744 | 1.12 (0.76–1.65) | 0.5682 | 1.08 (0.71–1.63) | 0.726 |
| FLT3-ITD low ratio, NPM1 wt | 0.81 (0.12–15.82) | 0.8505 | 1.55 (0.57–4.23) | 0.388 | 1.3 (0.41–4.1) | 0.6572 |
| FLT3-ITD high ratio, NPM1 wt | >99.99 (0–NA) | 0.9861 | 2.09 (0.97–4.49) | 0.0602 | 2.47 (1.14–5.34) | 0.0214 |
| FLT3wt, NPM1 + | 3.27 (1.21–11.42) | 0.0336 | 0.35 (0.21–0.59) | 0.0001 | 0.44 (0.27–0.71) | 0.0009 |
| FLT3-ITD low ratio, NPM1 + | 1.06 (0.28–7.03) | 0.9361 | 1.27 (0.62–2.62) | 0.5089 | 1.25 (0.58–2.7) | 0.5683 |
| FLT3-ITD high ratio, NPM1 + | 0.63 (0.25–1.83) | 0.3602 | 2.15 (1.33–3.47) | 0.0017 | 2.21 (1.31–3.75) | 0.0031 |
* CEBPA2 and CEBPA1 indicate the presence of double or single mutation, respectively.